Search results
Showing 801 to 850 of 8137 results
Agenda and papers of the NICE public board meeting on 16 December 2022
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Quick access to a range of journals and other evidence-based resources for health and social care staff in England.
Early value assessment is a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need. It champions stronger partnership working between regulatory, healthcare and research organisations to benefit people and better support innovators while ensuring value for money for the NHS
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
NICE broadens recommendation on chronic lung disease treatment
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .
Recommendation ID IPG746/01 Question Evidence on the safety of long-term tunnelled peritoneal drainage catheter insertion for refractory
Recommendation ID IPG745/01 Question Evidence on the safety of ab interno canaloplasty for open-angle glaucoma shows no major safety concerns
Recommendation ID NG37/03 Question Pilon fractures: In adults with closed pilon fractures, what method of fixation provides the best clinical
Recommendation ID NG37/01 Question Temporary dressings for up to 72 hours between wound excision and definitive soft tissue cover: What
Recommendation ID NG228/02 Question Predictors of death and disability: What variables predict death or disability for people with aneurysmal
Recommendation ID NG228/08 Question Transcranial doppler monitoring: What is the clinical and cost effectiveness of routine transcranial
Recommendation ID NG227/01 Question Ways of providing advocacy services: What is the effectiveness and acceptability of providing advocacy
Recommendation ID NG228/11 Question Vasopressors to manage delayed cerebral ischaemia: What is the clinical and cost effectiveness of vasopressors
Recommendation ID NG228/01 Question Timing of CT head scans: What is the relative accuracy of CT head scans at different time intervals
Recommendation ID NG228/05 Question Risk stratification tool to estimate risk of recurrence: What is the utility of a risk stratification
Recommendation ID NG228/06 Question Interventions for aneurysmal subarachnoid haemorrhage in people with major neurological deficit: What
Recommendation ID NG228/10 Question Intra-arterial therapies to manage delayed cerebral ischaemia: What is the impact of intra-arterial
Recommendation ID NG228/09 Question Intracranial hypertension: What is the impact of routine monitoring of intracranial hypertension on
Recommendation ID NG228/07 Question Managing acute hydrocephalus: What is the most clinically and cost-effective method of cerebrospinal
Recommendation ID NG37/02 Question Cystourethrogram: How accurate is the first CT scan with contrast (trauma scan) for detecting bladder
Recommendation ID NG228/03 Question Nimodipine: What is the clinical and cost effectiveness of nimodipine in the management of aneurysmal
Recommendation ID NG228/04 Question Novel endovascular interventions: What is the clinical and cost effectiveness of novel endovascular
Recommendation ID NG228/12 Question Blood pressure targets: What is the clinical and cost effectiveness of a lower blood pressure treatment
Recommendation ID NG228/13 Question Investigations for relatives: What is the clinical and cost effectiveness of investigations to detect
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
View recommendations for MTG75Show all sections
Our impact reports look at how the health and care system uses NICE's recommendations to improve people's health and care.
You can use our guidance and advice to find out what recommendations we have made about your condition or care needs. Our guidance goes beyond NHS...
Having a learning disability can affect how a person learns new things during their lifetime. They may need a range of extra support throughout life,...
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE
NICE is unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA848
NICE is making changes to simplify our offer to the life sciences industry
A review of the impact our evidence-based guidance has on improvements in adult social care.
A review of the impact our evidence-based guidance has on improvements in lung cancer.
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
Find out about the progress made by the health and care system in implementing NICE guidance on end of life care for adults
Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer
Find out about the progress made by the health and care system in implementing NICE guidance on respiratory conditions
Find out about the progress made by the health and care system in implementing NICE guidance on children and young people's healthcare
Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management
How NICE recommendations are being used to improve outcomes in priority areas of dementia care